(Health Korea News / Lee Chang-yong) ‘Pharmaceutical 24 Hours’ is a corner that shows you at a glance the short news related to pharmaceuticals and biotechnology that you might easily miss. It may seem like trivial news, but it can be valuable information to someone, so we summarize only the facts and show you in an easy-to-understand manner.
Mokam Life Science Research Institute, selected as government AI new drug solution development research institute
Mokam Life Science Research Institute was selected as one of five institutions to lead the ‘AI Solution Development’ research in the Artificial Intelligence (AI) New Drug Development Acceleration Project announced by the Ministry of Health and Welfare and the Ministry of Science and ICT.
The Ministry of Health and Welfare and the Ministry of Science and ICT are jointly promoting a project to reduce the cost and period required for new drug development by utilizing AI models based on federated learning with new drug development data held by industry, the medical community, and research institutes, with an investment of KRW 34.8 billion over five years from 2024 to 2028.
The Mokam Research Institute, together with Gwangju Institute of Science and Technology, Jeonbuk National University Industry-Academic Cooperation Foundation, Korea Advanced Institute of Science and Technology, and Eisen Science, took on the role of developing an artificial intelligence model for ADME/T prediction (a method for predicting the process by which drugs are absorbed into the body) to discover drug candidates using experimental data generated at each stage of new drug development.
LG Chem’s Rare Obesity Drug ‘LB54640’ Introduced by Rhythm Pharmaceuticals, Development Begins in Full Swing as Key Project
Rhythm Pharmaceuticals, a U.S. company that acquired a global license for a rare obesity drug from LG Chem, is entering full-scale development.
LG Chem announced on the 24th that its partner Rhythm Pharmaceuticals has begun administering the first subject of the phase 2 clinical trial of ‘LB54640’. Rhythm will recruit 28 patients with hypothalamic obesity aged 12 years or older who have difficulty controlling their appetite due to congenital or acquired hypothalamic dysfunction, and will evaluate the change in body mass index (BMI) at 14 weeks of drug administration as the primary efficacy evaluation index. In the extension study, the plan is to analyze safety after long-term administration for 52 weeks.
‘LB54640’ is a satiety signal gene (MC4R, Melanocortin-4 Receptor) agonist that LG Chem developed in-house and transferred its global license to Rhythm Pharmaceuticals in January. It is evaluated as a new drug substance with high potential, recording the largest amount of advance payment (USD 100 million) among domestic pharmaceutical industry technology exports in the first half of this year.
Dongkook Pharmaceutical Holds Symposium to Launch HA Filler ‘Cableline’ of Medical Aesthetic Line
Dongkook Pharmaceutical held a symposium to launch the hyaluronic acid (HA) filler ‘Cableline’ on June 22 and July 20.
Dongkook Pharmaceutical’s new HA filler Cableline is the first filler product released by Dongkook Pharmaceutical in 13 years since Belast. It is characterized by increasing the satisfaction and safety of practitioners and patients by incorporating the know-how of existing HA raw materials and filler manufacturing.
Cableline’s HA filler is based on a manufacturing technology called GTS-351 Technology, and includes technologies such as ThermoCross 24HA synthesis, ShapeSync 500 HA standardization, and German Purification System. Through these technologies, Cableline has optimized five elements: safety and stability, formability, ease of injection, and durability.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
